Eli Lilly is suing four telemedicine companies selling compounded versions of its blockbuster obesity drug Zepbound and its ...

Eli Lilly said on Wednesday it had sued four compounders for selling unapproved products containing tirzepatide, after a U.S.

$3,350,000 of ELI LILLY AND COMPANY lobbying was just disclosed, from Q1 of 2025, in a new Lobbying Disclosure Act filing. This included lobbying on issues like: "Issues related to intellectual ...

Eli Lilly (LLY) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

As for Eli Lilly’s 2025 outlook, it guided for full-year revenues between $58 billion and $61 billion, representing 32% growth at the midpoint. The company ... Next, I conduct a sensitivity ...

Eli Lilly Wednesday filed lawsuits against four telehealth companies alleging they are deceiving consumers by selling ...